Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib + Chemotherapy in Elderly FLT3 Mutated AML
NCT00783653Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Aug 2008
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in acute myeloid leukemia (AML), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoints: Definition of a recommended Phase III dose and Determination CTC version 3.0 grade 3-5 non-hematological toxicities. Started Aug 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00783653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00783653.